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Abstract  
The MLH1 c.2252_2253delAA mutation was found in 11 unrelated families from a restricted area south-
west of Turin among 140 families with mutations in the mismatch repair (MMR) genes. The mutation is 
located in the highly conserved C-terminal region, responsible for dimerization with the PMS2 protein.  
Twenty-five tumour tissues from 61 individuals with the c.2252_2253delAA mutation were tested for 
microsatellite instability (MSI) and protein expression. We compared the clinical features of these 
families versus the rest of our cohort and screened for a founder effect. 
All but one tumours showed the MSI-High mutator phenotype. Normal, focal and lack of MLH1 staining 
were observed in 16%, 36% and 48% of tumours, respectively. PMS2 expression was always lost. The 
mutation co-segregated with Lynch syndrome-related cancers in all informative families. All families but 
one fulfilled Amsterdam criteria (AC), a frequency higher than in other MLH1 mutants. This was even 
more evident for AC II (72.7% versus 57.5%). Moreover, all families had at least one colon cancer 
diagnosed before 50 years and one case with multiple LS-related tumours. Interestingly, a statistically 
significant (p=0.0057) higher frequency of pancreatic tumours was observed compared to families with 
other MLH1 mutations: 8.2% of affected individuals vs 1.6%. Haplotype analysis demonstrated a 
common ancestral origin of the mutation, which originated about 1550 years ago. 
The mutation is currently classified as having an uncertain clinical significance. Clinical features, tissue 
analysis and co-segregation with disease strongly support the hypothesis that the MLH1 
c.2252_2253delAA mutation has a pathogenic effect. 
 
Keywords Lynch syndrome; MLH1 mutations; MLH1-PMS2 dimerization; focal immunohistochemical 
expression; founder effect  
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Introduction 
 
Lynch syndrome (LS) is an inherited autosomal dominant cancer predisposition caused by deleterious 
germline mutations in any of four mismatch repair (MMR) genes: MLH1, MSH2, MSH6 and PMS2.  
Individuals affected by LS are at high risk of developing colorectal and endometrial cancer: the most 
common manifestation of this syndrome are tumours in the proximal colon (from the cecum to the splenic 
flexure), often synchronous and/or metachronous with an early age at onset (frequently younger than 45-
50 years of age). LS also confers an increased risk of developing cancer in several other organs, including 
ovary, stomach, small bowel, urothelium and central nervous system (CNS) [1,2]. As a consequence of 
loss of MMR function, neoplastic cells from individuals with LS show an absent or altered expression of 
the protein corresponding to the mutated gene and a generalized genomic instability, which is particularly 
evident at microsatellite loci. Both features can be demonstrated on tumour specimens by 
immunohistochemisty and microsatellite analysis.  
The MMR proteins work as heterodimers: MLH1 dimerizes with PMS2 and MSH2 with MSH6. In the 
absence of the usual partner, MLH1 can dimerize with PMS1 or MLH3 and MSH2 with MSH3 [3,4].  
The majority of Lynch families have constitutional mutations in either MSH2 or MLH1 while MSH6 and 
PMS2 are less frequently involved. Recently, a 5-tiered classification scheme to constitutional variants in 
MLH1, MSH2, MSH6 and PMS2, ranging from non pathogenic / low clinical significance (Class 1) to 
pathogenic (Class 5), has been proposed by The International Society for Gastrointestinal Hereditary 
Tumours (InSiGHT) [5]. 
Germline mutations in MLH1 have been identified throughout the entire gene, and are frequently located 
in the ATP binding domain and in the C-terminal region which is responsible for constitutive 
dimerization with the PMS2 protein [6-9]. 
Founder mutations, i.e. inherited by numerous descendants of a common ancestor, have been reported in 
the MMR  genes associated  with  LS [10-21]. 
We characterized a cohort of patients belonging to 11 LS families carrying the c.2252_2253delAA 
terminal mutation in the MLH1 gene. Aim of this work was to evaluate the clinical effect of this mutation 
and its possible founder origin given the high frequency in LS patients from Piedmont (Italy), particularly 
in the Turin area.  
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Patients and methods 
Subjects and samples  
The c.2252_2253delAA in MLH1 exon 19 was found in 11 apparently unrelated families among 140 
families harbouring germline MMR mutations (51 in MLH1, 74 in MSH2 and 15 in MSH6) identified in 
index cases undergoing genetic analysis for suspected LS in the Turin Medical Genetics Unit from 2001 
to middle 2013. Two hundred and seventy-eight control subjects from Piedmont were tested for the 
presence of the c.2252_2253delAA mutation. 
Signed informed consent was obtained from all subjects included in this study, which fulfilled the policies 
of the local ethical committee. For each family, geographical origin was collected and pedigrees were 
reconstructed collecting information about the relatives' surnames going back three to five generations: no 
evidence that the 11 families are closely related was found.  
The families carrying the c.2252_2253delAA mutation are listed in Table 1.  
Histological samples from 23 bowel and 2 endometrial tumours (13 from probands and 10 from family 
members) were retrieved for microsatellite analysis and immunohistochemistry. All tumours were revised 
for classification according to the WHO recommendations [22,23].
 
 
 
DNA extraction  
Constitutional DNA of probands, family members and controls was obtained from peripheral blood using 
the QIAamp DNA Blood Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's 
instructions. 
Paraffin embedded tumour sections 7-10 m thick were manually microdissected to obtain samples with 
tumour cells purity over 80%. After deparaffinization, DNAs from both tumour and normal mucosa were 
isolated following an overnight digestion with lysis buffer and proteinase K (Qiagen GmbH).  
 
Immunohistochemistry  
Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissues. Slides were 
incubated with mouse monoclonal antibodies against MLH1 (clone G168-15; BD PharMingen, San 
Diego, CA, USA), MSH2 (clone G219-1129; BD PharMingen), MSH6 (clone 44; BD Transduction 
Laboratories, San Jose, CA, USA), and PMS2 (clone A16-4; BD PharMingen) proteins. Visualization 
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was performed by application of HRP-linked secondary antibody (EnVision DakoCytomation, Glostrup, 
Denmark) and diaminobenzidine [24-26]. Immunohistochemistry analysis results have been confirmed on 
a different sample from the same cancer. 
 
Detection of Microsatellite Instability 
Microsatellite Instability (MSI) status was tested matching the length of three mononucleotide 
microsatellite markers (BAT25, BAT26 and BAT40) between tumour and normal DNA from all 25 
available cancers. A tumour was considered to have high microsatellite instability (MSI-H) if at least 2/3 
of the amplified markers were unstable [24,27]. 
  
DHPLC, MLPA and sequencing 
Screening for point mutations was performed by DHPLC analysis (Transgenomic, Inc., Omaha, NE, 
USA). PCR products with heteroduplex profiles were sequenced on an ABI 3100 Avant sequencer 
(Applied Biosystems, Foster City, CA, USA). Large deletions were screened
 
using SALSA MLPA KIT 
P003 MLH1/MSH2 [28], according to the manufacturer's instructions (MRC-Holland, Amsterdam, The 
Netherlands). Genotyping of the 278 controls was performed by DHPLC analysis. 
 
RNA extraction and transcript analysis 
The RNA of selected cases (M1/19-4, M1/19-6 and M1/19-7) was extracted from blood collected in 
PAXGene RNA blood tubes (PreAnalytics GmbH, Hombrechtikon, Switzerland) using the PAXgene 
Blood RNA kit (Qiagen GmbH). The cDNA was generated with the Transcripter first strand cDNA 
synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany). Reverse Transcription-PCR 
amplification was performed using forward (M1-iex18F: AATTGGGACGAAGAAAAGGAA) and 
reverse (M1-3UTR2: AAAGGAATACTATCAGAAGGCAAG) primers for exon 18 and exon 19 
(3’UTR), respectively. 
 
Mutation Nomenclature and reference sequence 
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Mutations were named following HGVS recommendations [29]. The MLH1 gene and mRNA reference 
sequences are NG_007109.2 and NM_000249.3, respectively. Markers positions on chromosome 3 are 
derived from the UCSC Genome Browser, GRCh37/hg19 assembly (http://genome.ucsc.edu/) 
 
Haplotype analysis  
Data analysis from HapMap (release 24, CEU population) and Haploview v. 4.11 [30] led to the 
identification of six Tag SNPs (Table 2). The rs193922366 ins/del polymorphism in the 3’UTR region of 
MLH1 was also analyzed. Ten additional microsatellites were retrieved from UCSC (GRCh37/hg19) to 
complete the study. In total, 17 polymorphic markers spanning 7.8 Mb on chromosome 3 were tested. 
Markers’ location on chromosome 3 and physical distance are shown in Fig. 1. 
 
Statistical Analysis 
Adjusted chi-squared statistic [31] was used to test homogeneity of proportions between groups from 
family-clustered data.  
The age of the MLH1 c.2252_2253delAA mutation was estimated using DMLE+2.3, which uses Markov 
Chain Monte Carlo algorithm for Bayesian estimation [32]. For the population growth a rate of 1.05 fold 
per generation was considered according to Risch et al [33]. Genotyped markers included 7 SNPs and 10 
microsatellites. 
 
Results 
 
Eleven apparently unrelated index cases undergoing genetic analysis for suspected LS were found to 
carry the same mutation in the last exon of MLH1, c.2252_2253delAA (p.Lys751Serfs*3). The mutation 
leads to a frameshift in the mRNA and a hypothetical shorter protein due to the generation of an early 
stop codon after the insertion of two novel amino acids at codons 751 and 752. The c.2252_2253delAA 
mutation was not found in 278 controls from the Piedmont population and is not reported in the Exome 
Variant Server (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, 
http://evs.gs.washington.edu/EVS/, accessed March 2014, release ESP6500SI-V2 including 6503 
samples). 
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cDNA analysis, performed on 3 of 11 index cases, showed in all samples the balanced presence of both 
the wild-type and the r.2252_2253delAA transcript (as shown in Online Resource 1).  
We subsequently extended the analysis to 61 relatives: the mutation was present in all the 12 subjects 
affected by LS related cancers. Among 49 healthy relatives the predictive test led to the identification of 
14 additional mutation carriers, all under 50 years of age at the moment of testing (Table 1). 
Clinical features of the 11 families are summarized in Table 1 and pedigrees are available as Online 
Resource 2. Ten of the 11 families fulfilled the Amsterdam criteria (AC) while one family met the 
Bethesda criteria. Compared to the rest of the cohort (140 mutated families overall), MLH1 
c.2252_2253delAA mutant families fulfilled AC more frequently than other MLH1 mutants (90.9% 
versus 80%), and this was more evident for AC II (72.7% versus 57.5%). All MLH1 
c.2252_2253delAA mutant families had at least one colon cancer diagnosed before 50 years of age 
and at least one case with multiple LS related primary tumours (the latter were present in 70% of 
other MLH1, 77% of MSH2 and 66.6% of MSH6 mutant families). It is noteworthy that 7/11 families 
(63.6%) had more than one case with multiple LS related primary tumours, compared to 35% of 
other MLH1, 33.8% of MSH2 and 13.3% of MSH6 mutant families (see Online Resource 3). 
Altogether, the median age at onset of the first LS related cancer in MLH1 c.2252_2253delAA mutant 
families was 49 years (from 23 to 80 years): at diagnosis 30/56 subjects (53.6%) were younger 
than 50, fifteen of which  were below 40 years of age. Among all LS related tumours, 59/86 (68.6%) were 
colorectal cancers; 37.7% of affected individuals showed LS related extra-colonic cancers at onset 
from the endometrium, pancreas, stomach, small bowel, biliary tract and central nervous system 
(CNS). In particular, pancreatic cancer was more frequent (5 tumours among 61 affected individuals, 
8.2%) compared to affected subjects from families with other MLH1 (1.6%, p=0.0057), MSH2 (2.4%, 
p=0.04) and MSH6 (3.8%, p=n.s.) mutations. Overall, pancreatic cancer was present in 5/11 (45.4%) 
of MLH1 c.2252_2253delAA families. No tumours of the upper urinary tract or the ovary nor 
sebaceous skin neoplasias were observed. 
Table 3 describes the histological features of available tumour specimens from carriers of the 
c.2252_2253delAA germline mutation. Of the 25 reviewed tumours, 23 were adenocarcinomas of the 
bowel and 2 of the endometrium (endometrioid type). Twelve out of 25 (48%) were moderately 
differentiated, 8 (32%) poorly differentiated and 5 (20%) well differentiated. Among bowel tumours, 11 
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out of 23 (47.8%) had a mucinous component (<50%), 6 (26.1%) were mucinous, and the remaining 6 
(26.1%) had no mucinous component.  
High MSI was found in all but one analyzed tumours (96%), in which low MSI was found, a proportion 
similar to MSH2 carriers in our cohort (94.6%) but slightly higher than carriers of other MLH1 mutations 
(91.3%) or MSH6 mutations (82.3%). Immunohistochemistry (Fig. 2) showed complete loss of the MLH1 
protein in only 12/25 (48%) cancers; 9/25 cancers (36%) showed a focal staining with or without 
weakened intensity, whereas in 4/25 specimens (16%) MLH1 was normally expressed. For comparison 
purpose, analysis of 43 tumour tissues from individuals with other MLH1 mutations, all located outside 
exon 19, showed a normal MLH1 expression in 7 (16.2%) and a focal expression in 1 (2.3%) cancers. 
Five of the seven cancers with normal MLH1 expression were from carriers of splicing mutations. In 
particular, 3 cancers were from carriers of the c.545+3A>G mutation, for which cDNA analysis was not 
performed by us but has been shown to cause aberrant splicing leading to the creation of a premature stop 
codon [34] and 2 from carriers of the c.589-2A>G mutation, for which cDNA analysis showed the 
skipping of the first 4 bases of exon 8 leading to a frameshift and the creation of a premature stop codon. 
The remaining mutations in which a normal MLH1 expression was observed were an in frame deletion in 
exon 16 and a truncating mutation in exon 18. The colon cancer with focal MLH1 expression was from a 
female carrier of the splicing defect c.589-17T>A in which RNA-cDNA analysis showed the in frame 
retention of the last 15 nucleotides of intron 7. 
Normal MLH1 expression was found in normal mucosa adjacent to cancer in all samples. In the 23 
tumours from individuals  with the c.2252_2253delAA mutation tested for PMS2 expression, the protein 
was always lost. MSH2 and MSH6 were normally expressed in all tested cancers. A second sample from 
the same tissue was tested for each of the 25 analysed tumours, with no discordant results.  
Haplotypes were reconstructed by genotyping all available informative relatives from 8 families, 
excluding families M1/19-7, M1/19-8 and M1/19-9 in which only the index case was available. A unique 
haplotype segregates with the c.2252_2253delAA mutation in all fully informative families spanning 1.7 
Mb from marker 16xTG to 18xGA, while markers centromeric and telomeric to this region are not shared 
by all mutated families (Table 4). This haplotype belongs to a single CEU haplotype as defined by data 
analysis of 6 SNPs from HapMap and Haploview (marked as haplotype number 2 in Table 2) and 
includes the CTT deletion polymorphism in the 3’UTR of MLH1 (c.*35_*37delCTT, rs193922366). 
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In family M1/19-8, for which only the index case was available, the markers’ phase was deducted on the 
basis of the CEU haplotypes: only two SNPs’ phases were possible, one of which coincided with the 
“mutated” haplotype. This was not possible for the index case of family M1/19-7 in which different 
phases were possible, while M1/19-9 was homozygote for the SNPs defining CEU “haplotype 2”. 
It is noteworthy that the genotypes of the 4 families that aren't fully informative are compatible with the 
same 1.7 Mb haplotype mentioned above (Table 4). 
The age of the c.2252_2253delAA mutation predicted by the DMLE+2.3 software is 62 generations 
(95% CI: 28-96), corresponding to about 1550 years. 
The wild-type haplotypes identified in our families are listed in Online Resource 4 and match 6 out of 8 
CEU haplotypes as defined by tag SNPs. Taking into consideration microsatellites, 23 different 
haplotypes were defined. The shared region in wild-type haplotypes spans about 0.1 Mb, compared to 1.7 
Mb in the “mutated” haplotype.  Only two haplotypes (2.pol), both belonging to CEU “haplotype 2”, 
carry the rs193922366 delCTT polymorphism and overlap with the “mutation-haplotype” for the same 
0.1 Mb region mentioned above, but differ for the majority of microsatellites.  
 
Discussion 
 
The MLH1 c.2252_2253delAA mutation is the most frequently recurring LS mutation found in our 
laboratory:  apart from a MSH2 exon 8 deletion with founder effect identified in 8 Sardinian families [21], 
the other recurrent mutations were found in 2 to 4 different families only. Overall, 21.6% of the families 
with a MLH1 mutation identified in our laboratory carried the c.2252_2253delAA mutation. The six 
other recurrent MLH1 mutations found in our cohort have not been tested for a founder effect. 
The c.2252_2253delAA mutation has previously been reported in the InSiGHT LOVD database 
(http://www.insight-group.org/variants/database/) in a Korean family [35-37], a Danish family [38], 
and in three other occurrences as unpublished data from the UK, Germany and Australia. No details 
about families nor tumour tissue analysis are available.  
Two different mutations involving the same nucleotides are also reported in the LOVD database. The 
missense variant c.2252A>G (p.Lys751Arg) has been classified as likely not pathogenic (Class 2) . The 
duplication c.2252_2253dupAA, which leads to a frameshift in the mRNA and is predicted to result in a 
protein longer by 26 amino acids, has been reported in three different families either with MSI-H and lack 
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of MLH1 expression [39], MSS (no information on MLH1 expression) [40] or in which tumour tissue had 
not been tested [41] and has been classified as uncertain (Class 3). The finding of both deletions and 
duplications of the same nucleotides in different cohorts may be explained by presence of three 
consecutive Adenines in the position c.2251_2253. 
Many founder mutations associated with LS have been reported in the MLH1 gene [10-15]. In Italy, a 
founder MLH1 mutation was found in six Lynch families originating from a relatively small geographic 
area of Northern Italy [42,43] 
 
and three other have been described in Southern Italy [44].  
Haplotype analysis of the 11 families with the c.2252_2253delAA mutation showed a shared haplotype 
spanning 1.7 Mb in all 8 fully informative families. It is of note that the heterozygous markers in the three 
remaining families are compatible with this “mutation-haplotype”. The shared haplotype includes the 
CTT deletion in the 3’UTR region, which is present in only two wild-type haplotypes (see Online 
Resource 4). As these matched the “mutation-haplotype” for some 0.1 Mb, we can assume that the 
c.*35_*37delCTT deletion was the first mutational event on the ancestral “CEU 2” haplotype, followed 
by further recombination or microsatellite mutations, and lastly by the occurrence of the 
c.2252_2253delAA mutation, about 1550 years ago. 
The evidence of a common ancestor obtained by haplotype analysis is coherent with the geographical 
origin of the 11 families, all from a 45 km-wide area south of Turin, Piedmont. 
Clinical data showed a high cancer incidence in families carrying the c.2252_2253delAA mutation. A 
higher proportion of families fulfilled AC compared to other MLH1 mutants, and this was more evident 
for AC II. All families had at least one colon cancer diagnosed before 50 years of age and at least one 
case with multiple LS related primary tumours; almost two-thirds of the families had more than one 
case with multiple LS related primary tumours. 
A high frequency of extra-colonic cancer was observed in subjects with the c.2252_2253delAA mutation. 
Interestingly, pancreatic cancer was significantly more frequent compared to carriers of other MLH1 
mutations. Overall, 45.4% of families reported the presence of pancreatic cancer. This  is higher than 
the frequencies reported up to date in other surveys, none of which was over 25% [45 -47]. Our data  
are evocative of an increased pancreatic cancer risk in families with the c.2252_2253delAA mutation. 
Since haplotype analysis demonstrated a common origin of the 11 families, we cannot rule out that the 
observed increased frequence of pancreatic cancer is actually due to another shared factor of genetic 
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predisposition. However, to our knowledge no genes with a demonstrated role in pancreatic cancer are 
located inside the haplotype shared by the families carrying the mutation. 
No tumours of the upper urinary tract and the ovary were observed. This is consistent with published 
data, as they are more frequently observed in MSH2 [48] and MSH6 [49] mutated families, 
respectively. 
Tissue analysis showed high microsatellite instability in all but one tested tumours from subjects with the 
c.2252_2253delAA mutation. 
In contrast, complete loss of MLH1 expression was found in only about half of the analyzed 
tumours, whereas about one third had focal immunostaining and the remaining had normal 
expression. Unusual staining patterns have been previously reported and do not seem to depend on the 
anti-MLH1 antibody used [50].
  
It has been suggested that different kinds of second hits can result in 
variable MLH1 immunostaining patterns in tumours of individuals carrying the same germinal mutation 
[51]. The possible association of the c.2252_2253delAA mutation with different somatic mutations 
in the wild type allele may lead to different expression patterns, from the complete absence of the 
MLH1 protein to the complete expression of a non-functional protein product. 
Immunohistochemistry analysis results support this hypothesis, considering that in all three cases in  
which distinct tumours from the same patient were analyzed, clearly different immunostaining 
patterns were observed (Table 3). 
A positive IHC staining may be explained by the presence of a mutant MLH1 protein catalytically 
inactive but antigenically intact. This has been shown for some missense mutations in the N-terminal 
ATPase pocket or in the C-terminal PMS2 binding region, which show an impaired MMR activity and no 
decrease in protein expression [52-54]. Normal MLH1 expression, however, has also been described in 
tumours from subjects with small and large in-frame deletions and truncating mutations [51,55]. As the 
c.2252_2253delAA mutation is located in the last exon of MLH1, it is unlikely that the mutant mRNA is 
degraded by nonsense-mediated decay (NMD) [56]. Accordingly, Sanger sequencing of cDNA by 3 
different carriers showed the balanced presence of both the wild-type and mutated transcripts (as shown 
in Online Resource 1). It is of note that Sanger sequencing is not a quantitative method and may therefore 
miss small imbalances that might be detected using more sensitive techniques (i.e. primer extension). The 
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presence of the mutated transcript, however, does not necessarily imply that the mutant MLH1 protein is 
correctly expressed nor stable.  
It has been previously reported that terminal MLH1 defects prevent the formation of a stable complex 
with PMS2, resulting in an impaired DNA mismatch repair function [6,9].
 
Although dimerization is not 
required for nuclear localization, the MLH1-PMS2 heterodimer is imported in the nucleus more 
efficiently than either MLH1 or PMS2 monomers [57]. While the MLH1 protein is stable when expressed 
alone, PMS2 is quickly degraded if not bound to MLH1 [9]. 
The c.2252_2253delAA mutation is predicted to abolish 6 of the last 8 MLH1 amino acids, which are 
highly conserved in the evolution of eukaryotes (as shown in Online Resource 5) and therefore, even if 
the mutant MLH1 protein is expressed, it is likely that binding to PMS2 is impaired.  Accordingly, PMS2 
expression was lost in all analyzed tumour samples from individuals carrying the c.2252_2253delAA 
mutation. 
In our cohort, a normal MLH1 expression was not limited to tumours from individuals with the 
c.2252_2253delAA mutation as it was observed with the same frequency in tumours from individuals 
with other MLH1 mutations, all of which located outside exon 19 and all but one resulting in a stop 
codon. Unfortunately, data about IHC testing for PMS2 is not available for these cases as it was not 
routinely performed years ago. 
Although the mechanism leading to MLH1 protein focal expression has not been clarified, it is 
noteworthy that in our experience this abnormal pattern has not been identified in patients with other 
MLH1 mutations, with the exception of one tumour from a subject with a different MLH1 mutation, a 
splicing defect leading to the in frame retention of the last 15 nucleotides of intron 7. 
The antigenic epitopes for the four anti-MMR antibodies are particularly sensitive to fixation and 
therefore immunostaining patterns should only be assessed in well-fixed regions of the tissue section [26].
 
In our experience of immunohistochemistry analysis, only few tumour tissues have shown weak, focal or 
weak focal MMR protein staining. These expression patterns, however, were usually seen for more than 
one protein in the same specimen and were interpreted as inadequacy of the sample. In the present study 
we did exclude that focal staining was due to tissue poor preservation, since normal MLH1 expression 
was found in the normal mucosa adjacent to cancer in all samples, or to an erroneous interpretation due 
to the mucinous component of the tumour; moreover MSH2 and MSH6 proteins were normally 
  
14 
expressed in the nuclei of both cancer and normal mucosa of all samples. The focal MLH1 
expression was unrelated to histological features of the analyzed tumours (cancer site, grading, 
mucinous component). We can speculate that this very terminal frameshift mutation leads to a MLH1 
protein not only unable to hetero-dimerize with PMS2 but also less stable and/or with a less efficient 
nuclear import as a monomer, which would explain its proper expression in only a few nuclei. 
The c.2252_2253delAA mutation has been classified as Class 3 (uncertain) by the Variant Interpretation 
Committee of the InSiGHT, mainly due to insufficient evidence. No familial or clinical data about 
previously reported cases is available.  
Our data strongly support the hypothesis that the MLH1 c.2252_2253delAA mutation has a pathogenic 
effect. The mutation is predicted to abolish 6 of the highly conserved last 8 amino acids of MLH1, in the 
C-terminal region which is responsible for constitutive dimerization with the PMS2 protein. Accordingly, 
all tested tumours from individual with the mutation lack PMS2 expression and all but one show MSI-H. 
The mutation co-segregates with disease in all informative families: it is noteworthy that all healthy 
subjects who were over 50 years of age at the moment of testing, including four aged 61-77, do not carry 
the mutation. The mutated families showed clinical features typical of LS including tumours at young age 
and multiple primary tumours in the same subject. Moreover, a high frequency of pancreatic cancer was 
observed.   
The c.2252_2253delAA mutation was absent in control subjects from the same Italian region and has not 
been reported as a normal polymorphism in the general population. 
Since haplotype analysis demonstrated a single origin of the mutated allele, we cannot rule out that the 
cause of LS in the 11 tested families is actually an unidentified MLH1 mutation residing on the same 
haplotype. This however is unlikely considering that the c.2252_2253delAA mutation has been reported 
in other two families ascertained for LS in different populations. 
 
Conflict of interest 
The authors declare no conflict of interest 
  
15 
 
Acknowledgements 
We thank Prof. Nicola Migone, for the precious advice and for providing the MLH1 multiple alignment 
and evolutionary evaluation, Dr Patrizia Pappi for sequences purification and technical support on 
microsatellite analysis and Mrs. Katia Pollato for further technical support on IHC and microsatellite 
analysis. 
 
References 
 
 
1. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis 
colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on 
HNPCC. Gastroenterology 116 (6):1453-1456 
2. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary 
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 
(4):261-268 
3. Acharya S, Wilson T, Gradia S, et al (1996) hMSH2 forms specific mispair-binding complexes with 
hMSH3 and hMSH6. Proc Natl Acad Sci U S A 93 (24):13629-13634 
4. Guerrette S, Acharya S, Fishel R (1999) The interaction of the human MutL homologues in hereditary 
nonpolyposis colon cancer. J Biol Chem 274 (10):6336-6341 
5. Thompson BA, Spurdle AB, Plazzer JP et al (2014) Application of a 5-tiered scheme for standardized 
classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat 
Genet 46 (2):107-115  
6. Kondo E, Suzuki H, Horii A, Fukushige S (2003) A yeast two-hybrid assay provides a simple way to 
evaluate the vast majority of hMLH1 germ-line mutations. Cancer Res 63 (12):3302-3308 
7. Raevaara TE, Korhonen MK, Lohi H et al (2005) Functional significance and clinical phenotype of 
nontruncating mismatch repair variants of MLH1. Gastroenterology 129 (2):537-549 
8. Mohd AB, Palama B, Nelson SE, Tomer G, Nguyen M, Huo X, Buermeyer AB (2006) Truncation of 
the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch 
repair. DNA Repair 5 (3):347-361 
  
16 
9. Kosinski J, Hinrichsen I, Bujnicki JM, Friedhoff P, Plotz G (2010) Identification of Lynch syndrome 
mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair. Hum Mutat 31 
(8):975-982 
10. Moisio AL, Sistonen P, Weissenbach J, de la Chapelle A, Peltomaki P (1996) Age and origin of two 
common MLH1 mutations predisposing to hereditary colon cancer. Am J Hum Genet 59 (6):1243-1251 
11. Jager AC, Bisgaard ML, Myrhoj T, Bernstein I, Rehfeld JF, Nielsen FC (1997) Reduced frequency of 
extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 
expression. Am J Hum Genet 61 (1):129-138 
12. Borras E, Pineda M, Blanco I et al (2010) MLH1 founder mutations with moderate penetrance in 
Spanish Lynch syndrome families. Cancer Res 70 (19):7379-7391 
13. van Riel E, Ausems MG, Hogervorst FB et al (2010) A novel pathogenic MLH1 missense mutation, 
c.112A > C, p.Asn38His, in six families with Lynch syndrome. Hered Cancer Clin Pract 8 (1):7 
14. Therkildsen C, Isinger-Ekstrand A, Ladelund S et al (2012) Cancer risks and immunohistochemical 
profiles linked to the Danish MLH1 Lynch syndrome founder mutation. Fam Cancer 11 (4):579-585.  
15. Tomsic J, Liyanarachchi S, Hampel H et al (2012) An American founder mutation in MLH1. Int J 
Cancer 130 (9):2088-2095 
16. Foulkes WD, Thiffault I, Gruber SB et al (2002) The founder mutation MSH2*1906G-->C is an 
important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J 
Hum Genet 71 (6):1395-1412 
17. Chan TL, Chan YW, Ho JW et al (2004) MSH2 c.1452-1455delAATG is a founder mutation and an 
important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. Am J 
Hum Genet 74 (5):1035-1042 
18. Lynch HT, Coronel SM, Okimoto R et al (2004) A founder mutation of the MSH2 gene and 
hereditary nonpolyposis colorectal cancer in the United States. JAMA 291 (6):718-724  
19. Stella A, Surdo NC, Lastella P et al (2007) Germline novel MSH2 deletions and a founder MSH2 
deletion associated with anticipation effects in HNPCC. Clin Genet 71 (2):130-139 
20. Perez-Cabornero L, Borras FE, Infante SM et al (2011) Characterization of new founder Alu-
mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype. Cancer Prev Res 
(Phila) 4 (10):1546-1555 
  
17 
21. Borelli I, Barberis MA, Spina F et al (2013) A unique MSH2 exon 8 deletion accounts for a major 
portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin. Eur J Hum 
Genet 21 (2):154-161 
22. Hamilton SR, Bosman FT, Boffetta P et al (2010) Carcinoma of the colon and rectum. In: Bosman 
FT, Carneiro F, Hruban RH, Theise ND (eds) WHO Classification of Tumours of the Digestive System, 
4
th
 edn. IARC Press, Lyon, pp 134-146 
23. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA (2003) Epithelial 
tumours and related lesions. In: Tavassoli FA, Devilee P (eds) Pathology and Genetics. Tumours of the 
breast and female genital organs, IARC Press, Lyon, pp 221-232 
24. Ruszkiewicz A, Bennett G, Moore J, Manavis J, Rudzki B, Shen L, Suthers G (2002) Correlation of 
mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated 
tumours. Pathology 34 (6):541-547 
25. Hansen TP, Nielsen O, Fenger C (2006) Optimization of antibodies for detection of the mismatch 
repair proteins MLH1, MSH2, MSH6, and PMS2 using a biotin-free visualization system. Appl 
Immunohistochem Mol Morphol 14 (1):115-121 
26. Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal 
cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of 
immunohistochemistry. J Mol Diagn 10 (4):293-300 
27. Boland CR, Thibodeau SN, Hamilton SR et al (1998) A National Cancer Institute Workshop on 
Microsatellite Instability for cancer detection and familial predisposition: development of international 
criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (22):5248-
5257 
28. Gille JJ, Hogervorst FB, Pals G, Wijnen JT et al (2002) Genomic deletions of MSH2 and MLH1 in 
colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 87 (8):892-897 
29. den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to 
describe complex mutations: a discussion. Hum Mutat 15 (1):7-12 
30. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and 
haplotype maps. Bioinformatics 21 (2):263-265 
  
18 
31. Donner A, Eliasziw M, Klar N (1994) A comparison of methods for testing homogeneity of 
proportions in teratologic studies. Stat Med 13 (12):1253-1264 
32. Reeve JP, Rannala B (2002) DMLE+: Bayesian linkage disequilibrium gene mapping. Bioinformatics 
18 (6):894-895 
33. Risch N, de Leon D, Ozelius L et al (1995) Genetic analysis of idiopathic torsion dystonia in 
Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 9 (2):152-159 
34. Pensotti V, Radice P, Presciuttini S et al (1997) Mean age of tumour onset in hereditary nonpolyposis 
colorectal cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair 
genes. Genes Chromosomes Cancer 19 (3):135-142 
35. Han HJ, Yuan Y, Ku JL et al (1996) Germline mutations of hMLH1 and hMSH2 genes in Korean 
hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 88 (18):1317-1319 
36. Yuan Y, Han HJ, Zheng S, Park JG (1998) Germline mutations of hMLH1 and hMSH2 genes in 
patients with suspected hereditary nonpolyposis colorectal cancer and sporadic early-onset colorectal 
cancer. Dis Colon Rectum 41 (4):434-440 
37. Shin YK, Heo SC, Shin JH, Hong SH, Ku JL, Yoo BC, Kim IJ, Park JG (2004) Germline mutations in 
MLH1, MSH2 and MSH6 in Korean hereditary non-polyposis colorectal cancer families. Hum Mutat 24 
(4):351-358 
38. Nilbert M, Wikman FP, Hansen TV et al (2009) Major contribution from recurrent alterations and 
MSH6 mutations in the Danish Lynch syndrome population. Fam Cancer 8 (1):75-83 
39. Pistorius SR, Kruppa C, Haas S et al (2000) Clinical consequences of molecular diagnosis in families 
with mismatch repair gene germline mutations. Int J Colorectal Dis 15 (5-6):255-263 
40. Wolf B, Henglmueller S, Janschek E et al (2005) Spectrum of germ-line MLH1 and MSH2 mutations 
in Austrian patients with hereditary nonpolyposis colorectal cancer. Wien Klin Wochenschr 117 (7-
8):269-277 
41. Sheng JQ, Fu L, Sun ZQ et al (2008) Mismatch repair gene mutations in Chinese HNPCC patients. 
Cytogenet Genome Res 122 (1):22-27 
42. Caluseriu O, Di Gregorio C, Lucci-Cordisco E et al (2004) A founder MLH1 mutation in families 
from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal 
cancer associated with protein elongation and instability. J Med Genet 41 (3):e34 
  
19 
43. Ponz De Leon MP, Benatti P, Di Gregorio C et al (2007) Genotype-phenotype correlations in 
individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. 
Scand J Gastroenterol 42 (6):746-753 
44. Lastella P, Patruno M, Forte G et al (2011) Identification and surveillance of 19 Lynch syndrome 
families in southern Italy: report of six novel germline mutations and a common founder mutation. Fam 
Cancer 10 (2):285-295 
45. Kastrinos F, Mukherjee B, Tayob N et al (2009) Risk of pancreatic cancer in families with Lynch 
syndrome. JAMA 302 (16):1790-1795 
46. Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, Fisher S, Hodgson SV (2008) Gene-related 
cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7 
(2):163-172  
47. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG (2009) 
Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with 
proven mutations. Clin Genet 75 (2):141-149 
48. van der Post RS, Kiemeney LA, Ligtenberg MJ et al (2010) Risk of urothelial bladder cancer in 
Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47 (7):464-470  
49. Pal T, Akbari MR, Sun P et al (2012) Frequency of mutations in mismatch repair genes in a 
population-based study of women with ovarian cancer. Br J Cancer 107 (10):1783-1790 
50. Hendriks Y, Franken P, Dierssen JW et al (2003) Conventional and tissue microarray 
immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J 
Pathol 162 (2):469-477 
51. Mangold E, Pagenstecher C, Friedl W et al (2005) Tumours from MSH2 mutation carriers show loss 
of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 
staining. J Pathol 207 (4):385-395 
52. Borras E, Pineda M, Brieger A et al (2012) Comprehensive functional assessment of MLH1 variants 
of unknown significance. Hum Mutat 33 (11):1576-1588 
53. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C (2007) Functional 
analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res 67 
(10):4595-4604 
  
20 
54. Hinrichsen I, Brieger A, Trojan J, Zeuzem S, Nilbert M, Plotz G (2013) Expression defect size among 
unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis. Clin Cancer Res 19 
(9):2432-2441 
55. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E (2002) 
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 
and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62 (12):3485-3492 
56. Frischmeyer PA, Dietz HC (1999) Nonsense-mediated mRNA decay in health and disease. Hum Mol 
Genet 8 (10):1893-1900 
57. Leong V, Lorenowicz J, Kozij N, Guarne A (2009) Nuclear import of human MLH1, PMS2, and 
MutLalpha: redundancy is the key. Mol Carcinog 48 (8):742-750 
  
21 
Fig. 1  Markers used to define the haplotypes carrying the MLH1 c.2252_2253delAA mutation 
 
 
  
a) Map of the markers surrounding the MLH1 gene  
b) Zoom-in of the region in which the tag SNPs are located. The position of rs193922366 (a three-
nucleotide ins/del: CTT/-) is also shown. The mutation is shown as a hollow circle 
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Fig. 2  Immunohistochemical staining of mismatch repair proteins 
 
 
 
 
a) absent MLH1 staining in colon cancer cells (left) and positive nuclear staining in normal colon mucosa 
(right); b1) focal MLH1 nuclear staining in colon cancer cells and b2) positive intense MLH1 staining in 
adjacent normal mucosa; c) positive nuclear MLH1 staining in colon cancer. 
d) absent PMS2 nuclear staining in colon cancer expressing MLH1 (left, same tumour of panel c) and 
positive staining in normal mucosa (right)  
(x 200 magnification) 
 
 
  
23 
Table 1  Clinical features of Lynch Syndrome families with the MLH1 c.2252_2253delAA mutation 
 
Family ID 
Clinical 
criteria
a
 
No. 
individuals 
affected by 
LS cancers
b
 
Median age 
at onset of 
the first LS 
cancer (min-
max age) 
No. 
Individuals 
with 
Colorectal 
cancers 
No. 
Colorectal 
cancers 
No. 
Endometrial 
cancers  
No. Gastric 
(Small 
bowel) 
cancers 
No. 
Pancreatic  
(Biliary 
tract) 
cancers  
CNS 
cancers
c
 
No. individual 
with 
synchronous 
tumours (No. 
of tumours) 
No. 
individuals 
with 
multiple 
primary 
tumours 
No. 
individuals 
affected by 
non-LS 
cancers or 
unknown site 
 
No. positive 
for the 
mutation / 
total 
affected 
relatives for 
confirmatory 
testing. 
No. positive 
for the 
mutation / 
total 
healthy 
relatives 
with 
predictive 
testing. 
M1/19-1 AC-I 5 68 (46-79) 5 7 0 0 (0) 0 (0) 0 1 (2) 2 0 0 1/4 
M1/19-2 AC-II 4 51.5 (38-69) 4 4 1 0 (0) 0 (1) 0 0 (0) 2 4 0 0/3 
M1/19-3 AC-II 3 43 (35-44) 1 1 1 1 (1) 1 (0) 0 0 (0) 2 0 1/1 3/4 
M1/19-4 AC-II 13 56 (26-80) 6 6 3 2 (1) 1 (0) 2 0 (0) 2 3 5/5  8/24 
M1/19-5 AC-II 7 44.5 (30-53) 6 8 2 1 (0) 0 (0) 0 1 (3) 2 0 3/3 1/4 
M1/19-6 AC-II 8 46.5 (35-61) 7 12 0 0 (0) 1 (0) 0 2 (3 and 4) 2 0 1/1 0/4 
M1/19-7 AC-I 3 66 (23-67) 3 4 0 0 (0) 0 (0) 0 0 (0) 1 1 0 0 
M1/19-8 AC-II 5 43 (37-60) 4 4 0 0 (0) 1 (0) 1 0 (0) 1 4 0 0 
M1/19-9 AC-II 7 51 (39-76) 4 5 1 1 (0) 0 (0) 1 0 (0) 1 2 0 0 
M1/19-10 AC-II 4 40 (36-59) 3 3 1 0 (0) 1 (0) 1 0 (0) 1 3 1/1 1/3 
M1/19-11 BR 2  (38-49) 2 5 0 0 (0) 0 (0) 0 0 (0) 2 0 1/1 0/3 
 
a 
Clinical criteria: AC-I (Amsterdam criteria type 1), AC-II (Amsterdam criteria type 2), BR (revised Bethesda criteria) 
b 
Number of individuals affected by Lynch syndrome (LS) tumours: colorectal, endometrial, gastric, small bowel, pancreatic, biliary tract, central nervous system 
(CNS). No ovarian and upper urinary or sebaceous cancers were present 
c
 CNS tumours have not been included in the median calculation because medical records were not available for confirmation 
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Table 2  CEU haplotypes defined by selected tag SNPs 
  CEU Haplotypes 
SNPs Gene 1 2 3 4 5 6 7 8 
rs1800743 MLH1 G G A G G A A G 
rs3774341 MLH1 C A A C A A A C 
rs1799977 MLH1 G A A A A A G A 
rs1558528 MLH1 A C C A C C C C 
rs9876116 MLH1 G A A G A A A G 
rs749072 LRRFIP2 T T C T C T C T 
          
Haplotype frequencies: % 33.3 26.6 17.5 15.0 4.1 1.6 1.6 0.8 
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Table 3  Histological features of 25 cancers from individuals with the MLH1 c.2252_2253delAA mutation 
 
  
WHO Classification of Tumours   IHC 
Subject ID
a
 Cancer site  
Histological 
diagnosis 
Differentiation 
grading 
Mucinous 
component: 
% 
MS-status MLH1 MSH2 MSH6 PMS2 
M1/19-1 rectum  
adenoma with 
invasive 
carcinoma  
well 5 MSI-H loss  No loss No loss loss  
M1/19-1 caecum adenocarcinoma moderately 40 MSI-H No loss No loss No loss loss  
M1/19-1.2 caecum adenocarcinoma moderately >50 MSI-H weak focal staining No loss No loss loss  
M1/19-1.3 transverse adenocarcinoma moderately 25 MSI-H loss  No loss No loss loss  
M1/19-2 caecum adenocarcinoma moderately 0 MSI-H weak focal staining No loss No loss loss  
M1/19-3 small bowel adenocarcinoma moderately 0 MSI-H loss  No loss ND
b
 ND 
M1/19-4 caecum adenocarcinoma poorly 0 MSI-H loss  No loss ND loss  
M1/19-4.2 descending adenocarcinoma moderately 10 MSI-H loss  No loss No loss loss  
M1/19-4.3 transverse adenocarcinoma moderately 30 MSI-H weak focal staining No loss No loss loss  
M1/19-4.4 Vater ampulla adenocarcinoma  well >50 MSI-H weak focal staining No loss No loss loss  
M1/19-5 caecum adenocarcinoma moderately 20 MSI-H weak focal staining No loss No loss loss  
M1/19-5 ascending adenocarcinoma moderately 0 MSI-H No loss No loss No loss loss  
M1/19-5 endometrium adenocarcinoma  well 0 MSI-L No loss No loss No loss loss  
M1/19-5.2 splenic flexure adenocarcinoma poorly 10 MSI-H weak focal staining No loss No loss loss  
M1/19-5.3 ascending adenocarcinoma well 5 MSI-H loss  No loss No loss loss  
M1/19-5.3 endometrium 
endometrioid 
adenocarcinoma 
well 0 MSI-H weak focal staining No loss No loss loss  
M1/19-5.4 hepatic flexure adenocarcinoma poorly 0 MSI-H loss  No loss No loss loss  
M1/19-6 splenic flexure adenocarcinoma poorly >50 MSI-H loss  No loss ND ND 
M1/19-7 caecum adenocarcinoma moderately 
signet ring 
cells 
MSI-H loss  No loss No loss loss  
M1/19-8 caecum adenocarcinoma poorly >50 MSI-H No loss No loss No loss loss  
M1/19-9 ascending adenocarcinoma poorly <5 MSI-H loss  No loss No loss loss  
M1/19-10 rectum adenocarcinoma poorly 45 MSI-H loss  No loss No loss loss  
M1/19-10.2 ascending adenocarcinoma moderately 10 MSI-H weak focal staining No loss No loss loss  
M1/19-11 transverse 
adenocarcinoma, 
signet ring cells 
poorly 
>50, signet 
ring cells 
MSI-H focal staining No loss No loss loss  
M1/19-11.2 sigmoid adenocarcinoma moderately 0 MSI-H loss  No loss No loss loss  
 
a 
Probands were coded as M1/19 followed by a number from 1 to 11. The .2, .3, etc. subcodes indicate different affected individuals belonging to  
the same family.  
b
ND = not determined 
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Table 4  Haplotypes identified in 11 probands with the MLH1 c.2252_2253delAA mutation 
 
Markers on chromosome 3: M1/19-1 M1/19-2 M1/19-3 M1/19-4 M1/19-5 M1/19-6 
D3S1277 285 297 283 281 283 291 283 291 283 285 285 291 
D3S1561 246 246 246 262 246 246 258 248 260 248 246 262 
16xTG 243 243 243 247 243 249 243 249 243 243 243 249 
19xAC 230 226 230 224 230 224 230 224 230 224 230 222 
14xAC 178 180 178 184 178 180 178 180 (178) (184) 178 180 
rs1800734 G G G A G G G G G G G G 
rs3774341 A A A A A C A C A A A C 
rs1799977 A A A A A G A G A A A G 
rs1558528 C C C C C A C A C C C A 
rs9876116 A A A A A G A G A A A G 
c.2252_2253delAA mut
a
 wt
b
 mut wt mut wt mut wt mut wt mut wt 
rs193922366* – CTT – CTT – CTT – CTT – CTT – CTT 
rs749072 T T  T C T T T T (T) (C) T T 
D3S1298 225 229 225 231 225 213 225 219 225 219 225 227 
D3S1260 286 284 286 290 286 284 286 286 286 274 286 286 
18xAC 212 222 212 210 212 214 212 206 212 218 212 210 
19xGA 172 172 172/178 170 168 172 172 172 172 172 168 
D3S3685 236 238 220 228 220 234 236 226 238 236 238 228 
                          
  M1/19-7 M1/19-8 M1/19-9 M1/19-10 M1/19-11     
  283/291 283/285 283/285 283 291 283 285     
  246/266 260/264 260/266 262 246 246 246     
  (243) (249) (243) (249) 243 243 243 249 243 249     
  (230) (224) (230) (224) (230) (226) 230 224 230 222     
  (178) (180) (178) (180) (178) (180) 178 180 178 180     
  (G) (A) G G G G G G G G     
  A A A C A A A C A C     
  A A A G A A A G A A     
  C C C A C C C A C A     
  A A A G A A A G A G     
  mut wt mut wt mut wt mut wt mut wt     
  (–) (CTT) (–) (CTT) (–) (CTT) – CTT – CTT     
  (T) (C) T T T T T T T T     
  225 225 225 225 225 225 225 231 225 217     
  286 286 286 286 286 286 286 286 286 286     
  212 212 212 214 (212) (222) 212 206 212 222     
  172 172 172 172 172/174 172 172 168 168     
  222/230 236 238 230/236 230 236 232 238     
 
*rs193922366 is a three-nucleotide ins/del: CTT/-; 
a
mut = mutated allele, 
b
wt = wild-type allele. 
The haplotype carrying the mutation is shown in bold. The 1.7 Mb region defined by the haplotype shared by all 
mutation carriers is marked in italics. 
For non informative markers inside the shared region, alleles have been attributed based on the haplotype carrying the 
mutation identified in informative families and are shown in brackets. 
For non informative markers outside the shared region, alleles could not be attributed and are separated by a "/". 
 
 
